0.6000USD-29.50%Mkt Cap: 15.50M USDP/E: —Last update: 2026-06-01
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap15.50M USD
Enterprise Value9.82M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-75.80M USD
Revenue/Share—
Last Price0.6000 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.45
PEG—
EV/EBITDA-0.14
EV/Revenue—
P/S—
P/B6.85
EPS (TTM)-2.58
EPS (Forward)-1.85
52W Range
0.56720% of range7.190
52W High7.190 USD
52W Low0.5672 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1826.09%
ROA-211.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.16M USD
CapEx (TTM)7.00K USD
FCF Margin—
FCF Yield-262.74%
Net Debt-13.39M USD
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity0.30
Current Ratio2.26
Quick Ratio1.57
Book Value/Sh0.1210 USD
Cash/Share0.5050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 4, 2024
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)7.500 USD
Target Range1.500 USD – 20.00 USD
# Analysts5
Ownership
Shares Out.28.00M
Float21.88M
Insiders1.19%
Institutions60.57%
Short Interest
Short Ratio8.0d
Short % Float8.97%
Short % Out.8.88%
Shares Short2.49M
Short (prev mo.)2.73M
Technical
SMA 500.9350 (-35.8%)
SMA 2001.713 (-65.0%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)307.10K
Avg Vol (10d)264.92K
Technical Indicators
RSI (14)43.0
MACD-0.0203
MACD Signal-0.0238
MACD Hist.+0.0035
BB Upper1.000 USD
BB Middle0.9052 USD
BB Lower0.8101 USD
BB Width21.03%
ATR (14)0.0832 USD
Vol Ratio (20d)1.10x